RESEARCH PAPER
Impact of HIV risk factors on survival in Iranian HIV-infected patients: A Bayesian approach to retrospective cohort
Submission date: 2016-06-17
Final revision date: 2017-01-09
Acceptance date: 2017-02-09
Publication date: 2017-05-30
HIV & AIDS Review 2017;16(2):100-106
KEYWORDS
TOPICS
epidemiology - population studiespsychological aspects of HIV and AIDSsocio-medical aspects of HIV and AIDS
ABSTRACT
Introduction: Human immunodeficiency virus (HIV) infection is recognized as a human health issue, and its social, cultural, economic, and political consequences lead to an extremely large problem for human health. The aim of this study is to evaluate association between risk factors and HIV-positive patient’s survival time.
Material and methods: In this population-based retrospective cohort study, a total of 245 positive HIV/AIDS infected patients were included. The required information were collected by an interview and blood testing. The interview was conducted by an expert and trained social worker, using a structured questionnaire. The demographic and risk factors of HIV infection factors such as: age, gender, job status, marital status, education attainment, prison status, injection drug user, heterosexual, homosexual, infected mothers, sexually transmitted disease, sex worker status, addiction, disease stage at diagnosis, CD4+ T-cell count, HBV, HCV, and AIDS were collected. The survival time of HIV patients was considered as a main outcome. Since there was a lot of censored data, we applied Gaussian Mixture Model.
Results: The analysis was done based on data of 205 (84%) patients. One hundred and sixty (78%) patients were male and the mean (SD) age of patients was 37.1 (9.3) years, varied from 4 to 65 years. During the study, 43 (21%) deaths were recorded. Median and mean with their 95% confidence intervals for survival time were 50.4 (range, 36.6-64.2) and 44.1 (range, 34.4-53.6) months, respectively, based on posterior distribution. Survival time was significantly correlated with the variables of disease stage at diagnosis time, sexually transmitted disease, CD4+ T-cell count, HBV, and AIDS. According to the sign of regression coefficients, there was strong negative correlation between survival time and disease stage at diagnosis time, sexually transmitted disease, HBV, and AIDS. Furthermore, positive correlation was found between survival times with CD4 level.
Conclusions: Since there are numerous national surveys running in Iran to fill in the information gaps on HIV prevalence and related risky behaviors among most at risk population, it is recommended to implement several integrated bio-behavioral surveillance surveys for hidden and hard-to-reach populations.
Material and methods: In this population-based retrospective cohort study, a total of 245 positive HIV/AIDS infected patients were included. The required information were collected by an interview and blood testing. The interview was conducted by an expert and trained social worker, using a structured questionnaire. The demographic and risk factors of HIV infection factors such as: age, gender, job status, marital status, education attainment, prison status, injection drug user, heterosexual, homosexual, infected mothers, sexually transmitted disease, sex worker status, addiction, disease stage at diagnosis, CD4+ T-cell count, HBV, HCV, and AIDS were collected. The survival time of HIV patients was considered as a main outcome. Since there was a lot of censored data, we applied Gaussian Mixture Model.
Results: The analysis was done based on data of 205 (84%) patients. One hundred and sixty (78%) patients were male and the mean (SD) age of patients was 37.1 (9.3) years, varied from 4 to 65 years. During the study, 43 (21%) deaths were recorded. Median and mean with their 95% confidence intervals for survival time were 50.4 (range, 36.6-64.2) and 44.1 (range, 34.4-53.6) months, respectively, based on posterior distribution. Survival time was significantly correlated with the variables of disease stage at diagnosis time, sexually transmitted disease, CD4+ T-cell count, HBV, and AIDS. According to the sign of regression coefficients, there was strong negative correlation between survival time and disease stage at diagnosis time, sexually transmitted disease, HBV, and AIDS. Furthermore, positive correlation was found between survival times with CD4 level.
Conclusions: Since there are numerous national surveys running in Iran to fill in the information gaps on HIV prevalence and related risky behaviors among most at risk population, it is recommended to implement several integrated bio-behavioral surveillance surveys for hidden and hard-to-reach populations.
REFERENCES (41)
1.
Kaushik S, Levy JA. HIV/AIDS. In: Desk encyclopedia of microbiology. 2nd ed. Schaechter M (ed.). Academic Press, Oxford 2010; pp. 640-663.
3.
World Health Organization. UNAIDS 2014. Available at: http://www. who.int/mediacentre/factsheets/fs360/en/.
4.
World Health Organization. UNAIDS report on the global AIDS epidemic 2010. Available at: http://www.unaids.org/globalre....
5.
Iranian Ministry of Health and Medical Education. Iran Country report on monitoring of the United Nations general assembly special session on HIV and AIDS. Iranian Ministry of Health, Tehran 2008.
6.
Mojtahedzadeh V, Razani N, Malekinejad M, et al. Injection drug use in rural Iran: Integrating HIV prevention into Iran’s rural primary health care system. AIDS Behav 2008; 12: 7-12.
7.
World Health Organization, UNAIDS, UNICEF. Epidemiological fact sheets on HIV/AIDS and sexually transmitted diseases of Islamic Republic of Iran 2004. Available at: http://data.unaids.org/publica....
8.
Montazeri A. AIDS knowledge and attitudes in Iran: results from a population-based survey in Tehran. Patient Education and Counseling 2005; 57: 199-203.
9.
Pisani E, Garnett GP, Grassly NC, et al. Back to basics in HIV prevention: focus on exposure. Br Med J 2003; 326: 1384-1387.
10.
Khalili H, Soudbakhsh A, Hajiabdolbaghi M, et al. Nutritional status and serum zinc and selenium levels in Iranian HIV infected individuals. BMC Infect Dis 2008; 8: 165.
11.
Obel N, Omland LH, Kronborg G, et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One 2011; 6: e22698.
12.
Larsen MV, Omland LH, Gerstoft J, et al. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study. Scand J Infect Dis 2010; 42: 917-923.
13.
Group DADS. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-1426.
14.
Magadi M, Desta M. A multilevel analysis of the determinants and cross-national variations of HIV seropositivity in sub-Saharan Africa: evidence from the DHS. Health Place 2011; 17: 1067-1083.
15.
Ataei B, Tayeri K, Kassaian N, et al. Hepatitis B and C among patients infected with human immunodeficiency virus in Isfahan, Iran: seroprevalence and associated factors. Hepat Mon 2010; 10: 188-192.
16.
Benaglia T, Chauveau D, Hunter DR, et al. Mixtools: An R package for analyzing finite mixture models. Journal of Statistical Software 2009; 32: 1-29.
18.
Lunn DJ, Thomas A, Best N, et al. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 2000; 10: 325-337.
19.
Chen L, Yang J, Zhang R, et al. Rates and risk factors associated with the progression of HIV to AIDS among HIV patients from Zhejiang, China between 2008 and 2012. AIDS Res Ther 2015; 12: 32.
20.
Pierre-Louis AM, Akala FA, Karam HS. Public Health in the Middle East and North Africa: Meeting the Challenges of the Twenty-first Century. World Bank Publications 2004.
21.
DeJong J, Jawad R, Mortagy I, et al. The sexual and reproductive health of young people in the Arab countries and Iran. Reproductive Health Matters 2005; 13: 49-59.
22.
Guaraldi G, Brothers TD, Zona S, et al. A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. AIDS 2015; 29: 1633-1641.
23.
Lemly DC, Shepherd BE, Hulgan T, et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis 2009; 199: 991-998.
24.
Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001; 15: 1115-1123.
25.
Cohen MH, Hotton AL, Hershow RC, et al. Gender-related risk factors improve mortality predictive ability of VACS Index among HIV- infected women. J Acquir Immune Defic Syndr 2015; 70: 538-544.
26.
Rezaianzadeh A, Hasanzadeh J, Alipour A, et al. Impact of hepatitis C on survival of HIV-infected individuals in Shiraz; South of Iran. Hepat Mon 2012; 12: 106.
27.
Grzeszczuk A, Wandalowicz AD, Jaroszewicz J, et al. Prevalence and Risk Factors of HCV/HIV Co-Infection and HCV Genotype Distribution in North-Eastern Poland. Hepat Mon 2015; 15: e27740.
28.
Lai YJ, Liu EY, Wang LM, et al. Human Immunodeficiency Virus Infection-Associated Mortality during Pulmonary Tuberculosis Treatment in Six Provinces of China. Biomedical and Environmental Sciences 2015; 28: 421-428.
29.
Akinyemi JO, Adesina OA, Kuti MO, et al. Temporal distribution of baseline characteristics and association with early mortality among HIV-positive patients at University College Hospital, Ibadan, Nigeria. Afr J AIDS Res 2015; 14: 201-207.
30.
Mirani G, Williams PL, Chernoff M, et al. Changing Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy. Clin Infect Dis 2015; 61: 1850-1861.
31.
Argemi X, Dara S, You S, et al. Impact of malnutrition and social determinants on survival of HIV-infected adults starting antiretroviral therapy in resource-limited settings. AIDS 2012; 26: 1161-1166.
32.
Badie BM, Nabaei G, Rasoolinejad M, et al. Early loss to follow-up and mortality of HIV-infected patients diagnosed after the era of antiretroviral treatment scale up: a call for re-invigorating the response in Iran. Int J STD AIDS 2013; 24: 926-930.
33.
Komati S, Shaw PA, Stubbs N, et al. Tuberculosis risk factors and mortality for HIV infected persons receiving antiretroviral therapy in South Africa. AIDS 2010; 24: 1849-1855.
34.
Carriquiry G, Fink V, Koethe JR, et al. Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean. J Int AIDS Soc 2015; 18: 20016.
35.
Ning S, Xue Z, Wei J, et al. HIV/AIDS related mortality in southern Shanxi province and its risk factors. Zhonghua Liu Xing Bing Xue Za Zhi 2015; 36: 245-249.
36.
Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998; 352: 1510-1514.
37.
Brugal MT, Domingo-Salvany A, Puig R, et al. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005; 100: 981-989.
38.
Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26: 335-343.
39.
May M, Gompels M, Delpech V, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 2011; 343: d6016.
40.
Antiretroviral Therapy Cohort Collaboration, Zwahlen M, Harris R, May M, et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38: 1624-1633.
41.
Razzaghi EM, Movaghar AR, Green TC, et al. Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J 2006; 3: 12.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
